MedTrace Logo

A Study of the PK Interaction of CXA-10 With Pravastatin and Vytorin® in Healthy Males

NCT02547402 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2016-05-03

No results posted yet for this study

Summary

This is an exploratory study in a small, well controlled group of healthy subjects to explore the effect of CXA-10 on pravastatin and Vytorin® (combination of simvastatin and ezetimibe).

Conditions

Interventions

DRUG

CXA-10

CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitrated oleic acid

DRUG

pravastatin

It is statin medicine used to lower cholesterol and triglycerides in the blood.

DRUG

Vytorin® (combination of simvastatin and ezetimibe)

It lowers bad cholesterol in the blood, and raises good cholesterol

Sponsors & Collaborators

  • Complexa, Inc.

    lead INDUSTRY

Principal Investigators

  • Thomas Blok, MD · Jasper Clinic, Michigan

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
30 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2016-01-31
Completion
2016-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02547402 on ClinicalTrials.gov